Tirzepatide 12.5 mg
  1. Home
  2. Mounjaro
  3. Tirzepatide 12.5 mg

Tirzepatide 12.5 mg

Tirzepatide 12.5 mg is a prescription dual GIP and GLP-1 receptor agonist used to improve glycemic control in adults with type 2 diabetes and, for certain formulations, to support chronic weight management. It is administered as a once-weekly subcutaneous injection using a sterile prefilled injection pen. The 12.5 mg strength is commonly prescribed during dose escalation or as part of maintenance therapy according to the prescribed treatment plan.

BUY NOW

Category

Tirzepatide 12.5 mg contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood glucose and body weight by enhancing glucose-dependent insulin secretion, reducing glucagon release, slowing gastric emptying, and promoting satiety. The 12.5 mg dose is typically prescribed after gradual dose escalation to provide enhanced metabolic control and support long-term treatment goals when clinically appropriate. Manufactured under stringent pharmaceutical quality standards, the sterile prefilled injection pen is engineered for precise subcutaneous administration and dependable clinical performance. Tirzepatide 12.5 mg should be used only under the supervision of a qualified healthcare professional according to the prescribed treatment plan.

Technical Specification

Specification Details
Product Name Tirzepatide 12.5 mg
Active Ingredient Tirzepatide
Strength 12.5 mg
Dosage Form Sterile Prefilled Injection Pen
Route of Administration Subcutaneous Injection
Storage Refrigerate at 2°C–8°C before first use

Product Also Known As

Tirzepatide 12.5 mg, Tirzepatide Injection 12.5 mg, Tirzepatide Prefilled Pen, Weekly Tirzepatide Injection, GIP GLP-1 Receptor Agonist, Diabetes Injection Pen, Tirzepatide Injectable Pen